The United States Patent and Trademark Office (USPTO) granted a new patent to Nexalin Technology, Inc. on Friday afternoon for their Deep Intracranial Frequency Stimulation (DIFS) device. This technology is designed as a non-invasive treatment for Alzheimer’s and dementia.
Nexalin Technology announced that USPTO has granted U.S. Patent No. 12,011,591, which covers their advanced DIFS medical device. The device uses a proprietary frequency-based waveform to provide deep brain stimulation in a pain-free and undetectable manner, focusing on Alzheimer’s and dementia-related brain diseases.
CEO Mark White emphasized the importance of this patent in expanding the company’s intellectual property and addressing the growing global market for dementia treatment. He highlighted the significant market potential due to the rising prevalence of dementia and substantial investments in research and development. Nexalin’s technology has shown clinical benefits for various neurological conditions, including treatment-resistant depression, migraines, anxiety, insomnia, addiction, and PTSD. The new patent demonstrates the potential of DIFS technology to improve the standard of care for mental health disorders like Alzheimer’s and dementia.
Nexalin Technology shares were up by 97.3%, trading at $2.15 at the time of writing, according to Benzinga Pro. This development marks a significant milestone for the company as they continue to innovate in the field of neurological treatments.
In conclusion, Nexalin Technology’s surge in shares on Friday afternoon was triggered by the USPTO awarding them a new patent for their DIFS device used to treat Alzheimer’s and dementia non-invasively. The patent covers their advanced medical device that uses a proprietary frequency-based waveform to provide deep brain stimulation without any pain or detection while focusing on brain diseases related to these conditions.
Nexalin Technology’s CEO Mark White highlighted how this patent would help expand their intellectual property rights and address the growing demand for dementia treatment worldwide due to its rising prevalence rate and substantial investments in research and development.
The company’s technology has already shown promising results in treating various neurological conditions such as depression, anxiety, insomnia addiction among others with plans to expand it further into other areas like PTSD.
The new patent presents an opportunity for Nexalin Technology to establish itself as a leader in providing cutting-edge treatments for mental health disorders like Alzheimer’s and dementia while creating long term value for its shareholders through innovation expansion opportunities.
